Mycobacterium bovis BCG is attenuated strain derived from M. bovis. It has been known to prevent childhood pulmonary
and meningeal tuberculosis and to treat superficial bladder cancer as immunotherapy. Administration of BCG has been
restricted to immune-deficient individuals since 2007 because of its combined complications. Which treated with
antituberculosis drugs based on assumption is fully responsive to these drugs. BCG Connaught showed more
susceptibility to the activity of isoniazid, ethambutol, kanamycin, ofloxacin, streptomycin, amikacin and capreomycin
than BCG Pasteur growing in J774A.1 cells. While the activity of rifampicin and levofloxacin was the same between the
two tested strains. The spectrum of intracellular drug action can be ordered based on a decreasing order of inhibitory
activity, as following rifampin > isoniazid > ethambutol > streptomycin > kanamycin> amikacin> ofloxacin>
capreomycin> levofloxacin against BCG Connaught. While rifampin > isoniazid > ethambutol > kanamycin =
streptomycin > ofloxacin> amikacin> levofloxacin> capreomycin for BCG Pasteur. There is a very limited publications
describe the activity of antituberculosis drugs against intracellular growing BCG strains